Immunovant (IMVT) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $7.08B
- As of Nov 13, 2026
- P/E
- -13.93x
- Trailing twelve months
- P/B
- 10.77x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -77.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $7.08B
- As of Nov 13, 2026
- P/E
- -13.93x
- Trailing twelve months
- P/B
- 10.77x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -77.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-13.93x
Net loss — not comparable
P/B
10.77x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$2.45
Earnings per share
BPS
$3.17
Book value per share
ROE
-77.3%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.45 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.17 of net assets.
- ROE — shareholder equity shrank by 77.3% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2027 Q2)
Net income increased from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Net income · same quarter, three years
Year-ago quarter -$127MUp
-$109M
Jul–Sep '24
-$127M
Jul–Sep '25
-$97M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 9, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 9, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Pande AtulDirector · Nov 11, 2026Open-market sale3,000 shares · $108KAvg. price $36116,731 shares held after
- Pande AtulDirector · Nov 11, 2026Option exercise3,000 shares · $25KAvg. price $8.43119,731 shares held after
- Girao TiagoChief Financial Officer · Oct 28, 2026Open-market sale6,606 shares · $188KAvg. price $28.5234,192 shares held after
- Stout Jay SChief Technology Officer · Oct 21, 2026Open-market sale2,595 shares · $75KAvg. price $28.94198,937 shares held after
- Gloria MelanieChief Operating Officer · Oct 7, 2026Open-market sale2,241 shares · $72KAvg. price $32.06217,060 shares held after
- Stout Jay SChief Technology Officer · Oct 7, 2026Open-market sale3,809 shares · $122KAvg. price $32.06
Show 2 price lots
- 2,213 shares × $32.06$71K
- 1,596 shares × $32.06$51K
- Van Tuyl ChristopherChief Legal Officer · Oct 7, 2026Open-market sale1,327 shares · $43KAvg. price $32.06175,218 shares held after
- Venker EricChief Executive Officer · Oct 2, 2026Open-market sale3,506 shares · $120KAvg. price $34.11257,075 shares held after
- Venker EricChief Executive Officer · Oct 1, 2026Disposition to the issuer85,886 shares · $2.9MAvg. price $33.65260,581 shares held after
- Venker EricChief Executive Officer · Oct 1, 2026Option exercise92,187 shares · $1.3MAvg. price $14.46346,467 shares held after
- Van Tuyl ChristopherChief Legal Officer · Sep 23, 2026Open-market sale2,846 shares · $103KAvg. price $36.36176,545 shares held after
- Pande AtulDirector · Aug 28, 2026Open-market sale1,500 shares · $65KAvg. price $43.27116,731 shares held after
- Pande AtulDirector · Aug 28, 2026Option exercise1,500 shares · $13KAvg. price $8.43118,231 shares held after
- Gloria MelanieChief Operating Officer · Aug 20, 2026Open-market sale3,056 shares · $135KAvg. price $44.16219,301 shares held after
- Pande AtulDirector · Jul 24, 2026Open-market sale1,500 shares · $60KAvg. price $39.8116,731 shares held after
- Pande AtulDirector · Jul 24, 2026Option exercise1,500 shares · $13KAvg. price $8.43118,231 shares held after
- Girao TiagoChief Financial Officer · Jul 23, 2026Open-market sale6,798 shares · $263KAvg. price $38.69240,798 shares held after
- Stout Jay SChief Technology Officer · Jul 23, 2026Open-market sale2,857 shares · $111KAvg. price $38.69205,341 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Immunovant (IMVT) stock information
NASDAQ
Immunovant (IMVT) is listed on NASDAQ. Its market capitalization is about $7.1B. On trailing-twelve-month earnings the P/E ratio is -13.93, and the P/B ratio is 10.77. Return on equity is -77.3%. These figures are computed in-house from official filings and are reference information only.
Immunovant — frequently asked questions
- What is the P/E ratio of Immunovant (IMVT)?
- On a trailing-twelve-month basis, IMVT trades at a P/E ratio of -13.93. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Immunovant?
- IMVT has a market capitalization of about $7.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.